Table 3 Positive findings in patients and multivariate analysis of statistically significant positive findings
Total | Sarcoma | Benign | p-value(sar. vs. ben.) | Sensitivity | Specificity | PPV (%) | NPV (%) | |
|---|---|---|---|---|---|---|---|---|
Age (≥49) | 31/63 (49.2%) | 14/15 (93.3%) | 17/48 (35.4%) | <0.001* | 0.93 | 0.65 | 45.2 | 96.9 |
Serum CA125 (≥35) | 17/63 (27.0%) | 6/15 (40.0%) | 11/48 (22.9%) | 0.193 | 0.40 | 0.77 | 35.3 | 80.4 |
Serum LDH (≥279) | 7 /63(11.1%) | 7/15 (46.7%) | 0/48 (0.0%) | <0.001* | 0.47 | 1.00 | 100.0 | 85.7 |
RI (≤0.4) | 28/63 (44.4%) | 7/15 (46.7%) | 29/48 (60.4%) | 0.348 | 0.47 | 0.40 | 19.4 | 70.4 |
MRI findings | 27/63 (42.9%) | 12/15 (80.0%) | 15/48 (31.3%) | <0.001* | 0.80 | 0.69 | 44.4 | 91.7 |
Cytological findings | 6/63 (9.5%) | 5/15 (33.37%) | 1/48 (2.1%) | <0.001* | 0.33 | 0.93 | 83.3 | 58.3 |
<multivariate analysis> | odds ratio | 95% CI | p-value | |||||
Age | 7.001×107 | [3.700, >1000] | 0.003* | |||||
Serum LDH | 2.304×109 | [15.775, >1000] | <0.001* | |||||
MRI findings | 0.420 | [0.014, 4.604] | 0.499 | |||||
Cytological findings | 4.784×108 | [19.554, >1000] | <0.001* |